Patients with LPLD
, which affects no more than one or two people per million, are unable to handle fat particles in their blood and are at risk of acute and potentially fatal inflammation of the pancreas.
It was also shown that Glybera significantly reduces the risk of pancreatitis in LPLD
Under the study, in an open label clinical trial (CT-AMT-011-02), 5 LPLD
subjects, in Quebec, Canada, were administered alipogene tiparvovec at a dose of 1 x 1012 genome copies per kg.
Pancreatitis is a major clinical symptom of LPLD
. It causes severe abdominal pain and often leads to hospitalisation of patients as well as other complications such as diabetes and early atherosclerosis.
Glybera is a gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD
) that is currently under review for marketing approval with the European Medicines Agency (EMA).
10 May 2011 - Dutch Amsterdam Molecular Therapeutics (AMS: AMT) gave on Tuesday a status update on Glybera (alipogene tiparvovec), its gene therapy product under development for the treatment of lipoprotein lipase deficiency (LPLD
23 November 2010 - Dutch Amsterdam Molecular Therapeutics (AMS: AMT) said today it has submitted its responses to the Day 120 questions posed by the European Medicines Agency (EMA) as part of the review process for Glybera, a gene therapy for lipoprotein lipase deficiency (LPLD
The technology has already been successfully applied to Glybera, a gene therapy for lipoprotein lipase deficiency (LPLD
), AMT said.
The company will use the proceeds from the offering to fund the registration process of its Glybera product that treats a rare disease called LPLD
. Because of a defective gene, LPLD
patients do not produce an enzyme that normally breaks down a certain type of fat-carrying particles in the blood.
M2 EQUITYBITES-June 29, 2011-AMT releases data on Glybera reducing risk of Pancreatitis in LPLD
patients(C)2011 M2 COMMUNICATIONS http://www.m2.com
Amsterdam Molecular Therapeutics (AMT)(Euronext:AMT), a human gene therapy company, announced on Friday the receipt of an opinion on its Marketing Authorisation Application (MAA) for Glybera (alipogene tiparvovec) as a potential therapy for Lipoprotein Lipase Deficiency (LPLD
This diagnostic tool rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD